| FNFPX | RGOIX | FNFPX / RGOIX | |
| Total Expense Ratio | 0.47 | 0.75 | 63% |
| Annual Report Gross Expense Ratio | 0.47 | 0.82 | 57% |
| Fund Existence | 5 years | 11 years | - |
| Gain YTD | 21.499 | 17.335 | 124% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 250 | 100000 | 0% |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 165B | 501M | 32,934% |
| Annual Yield % from dividends | 0.69 | 0.56 | 125% |
| Returns for 1 year | 14.96 | 13.54 | 111% |
| Returns for 3 years | 53.34 | 46.11 | 116% |
| Returns for 5 years | 37.09 | 35.29 | 105% |
| Returns for 10 years | N/A | 149.89 | - |
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| BIB | 76.07 | 0.67 | +0.88% |
| ProShares Ultra Nasdaq Biotechnology | |||
| IBRN | 29.23 | 0.16 | +0.54% |
| iShares Neuroscience and Healthcare ETF | |||
| FRDM | 48.53 | 0.19 | +0.39% |
| Freedom 100 Emerging Markets ETF | |||
| HBDC | 25.11 | 0.03 | +0.10% |
| Hilton Bdc Corporate Bond ETF | |||
| CAPE | 31.92 | N/A | +0.01% |
| DoubleLine Shiller CAPE US Equities ETF | |||